Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 483 of 483 entries
View as:

Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05446831 Org: User:
Start: 07/13/22 End: 12/01/23 Due: 12/01/24

Immediate Axillary Plasty With a Pedicled Muscle Flap for Breast Cancer Related Lymphedema Prevention

Phase: N/A Priority: Normal
NCT ID: NCT02318615 Org: User:
Start: 12/31/15 End: 08/31/20 Due: 08/31/21

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT04824352 Org: User:
Start: 04/01/21 End: 04/01/26 Due: 04/01/27

Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

Phase: N/A Priority: Normal
NCT ID: NCT03919539 Org: User:
Start: 12/01/19 End: 12/31/21 Due: 12/31/22

RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

Phase: N/A Priority: Normal
NCT ID: NCT03412266 Org: User:
Start: 02/01/18 End: 03/01/23 Due: 03/01/24

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)

Phase: N/A Priority: Normal
NCT ID: NCT05277480 Org: User:
Start: 03/01/22 End: 11/26/23 Due: 11/26/24

KPD Consolidation After ASCT in NDMM Patients

Phase: N/A Priority: Normal
NCT ID: NCT06879379 Org: User:
Start: 03/31/25 End: 03/31/29 Due: 03/31/30

Correlation Analysis Between Rotator Cuff Tear and the Superior Migration of Humeral Head

Phase: N/A Priority: Normal
NCT ID: NCT03358316 Org: User:
Start: 01/01/18 End: 01/01/19 Due: 01/01/20